Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark J Levis

Showing results (11-20 of 133) with videos related to

Pageof 14
Sort By:
Current Drug Targets|April 8, 2010
Bench to bedside targeting of FLT3 in acute leukemiaKeith W Pratz, Mark J Levis
Seminars in Hematology|June 27, 2015
FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid LeukemiaMichael R Grunwald, Mark J Levis
Leukemia & Lymphoma|November 3, 2017
Emerging molecular predictive and prognostic factors in acute myeloid leukemiaShannon R McCurdy, Mark J Levis
International Journal of Hematology|April 25, 2013
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistanceMichael R Grunwald, Mark J Levis
Current Hematologic Malignancy Reports|April 20, 2017
The Future of Targeting FLT3 Activation in AMLMark B Leick, Mark J Levis
Blood Advances|October 29, 2025
Reply to Gui and HouriganMark J Levis, Mehdi Hamadani, Yi-Bin Chen
NPJ Precision Oncology|September 10, 2024
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemiaJacob J Adashek, Max Brodsky, Mark J Levis
Expert Review of Clinical Pharmacology|September 30, 2017
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosisSabine Kayser, Mark J Levis, Richard F Schlenk
Therapeutic Advances in Hematology|June 3, 2014
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyondSeth A Wander, Mark J Levis, Amir T Fathi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
The Changing Landscape of Treatment in Acute Myeloid LeukemiaKristin Koenig, Alice Mims, Mark J Levis, et al.
Pageof 14

Showing results (11-20 of 133) with videos related to

Sort By:
Pageof 14
Current Drug Targets|April 8, 2010
Bench to bedside targeting of FLT3 in acute leukemiaKeith W Pratz, Mark J Levis
Seminars in Hematology|June 27, 2015
FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid LeukemiaMichael R Grunwald, Mark J Levis
Leukemia & Lymphoma|November 3, 2017
Emerging molecular predictive and prognostic factors in acute myeloid leukemiaShannon R McCurdy, Mark J Levis
International Journal of Hematology|April 25, 2013
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistanceMichael R Grunwald, Mark J Levis
Current Hematologic Malignancy Reports|April 20, 2017
The Future of Targeting FLT3 Activation in AMLMark B Leick, Mark J Levis
Blood Advances|October 29, 2025
Reply to Gui and HouriganMark J Levis, Mehdi Hamadani, Yi-Bin Chen
NPJ Precision Oncology|September 10, 2024
Complete morphologic response to gilteritinib in ALK-rearranged acute myeloid leukemiaJacob J Adashek, Max Brodsky, Mark J Levis
Expert Review of Clinical Pharmacology|September 30, 2017
Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosisSabine Kayser, Mark J Levis, Richard F Schlenk
Therapeutic Advances in Hematology|June 3, 2014
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyondSeth A Wander, Mark J Levis, Amir T Fathi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 3, 2020
The Changing Landscape of Treatment in Acute Myeloid LeukemiaKristin Koenig, Alice Mims, Mark J Levis, et al.
Pageof 14